Transformation in Trials

Send us a textSebastian Andruszczak, Chief Growth Officer at Holisticon (part of the Nexer Group), brings fresh perspective to the conversation around generative AI adoption in pharmaceutical companies. Drawing from his unique background in sales, marketing, and technology, Sebastian cuts through the hype to address fundamental challenges that prevent successful AI implementation in life sciences.The conversation reveals a critical insight often overlooked in the rush to adopt new technology: without proper data governance, organizations risk "scaling disaster." Sebastian walks us through the specific challenges pharmaceutical companies face - from ever-changing data sources creating inconsistent AI responses, to linguistic variations causing subtle differences in interpretation across global teams. These issues become magnified when implementing AI at enterprise scale, potentially undermining the very efficiencies these technologies promise.Sebastian outlines a methodical, four-part approach to building effective AI systems: starting with data governance fundamentals, then data engineering, followed by traditional machine learning, and finally generative AI applications. This structured approach has proven successful for companies like Beringer Ingelheim, whose ambitious knowledge management system has already saved one million working hours by processing over 800,000 documents across 200 departments in 70+ countries.What makes this episode particularly valuable is Sebastian's candid assessment of the industry's current state. While acknowledging the transformative potential of strategic AI initiatives in drug discovery and knowledge management, he challenges the fear-driven implementation happening in many organizations. His "magic wand" wish for the industry reflects this pragmatism: focus first on data quality - a decades-old challenge that finally has the perfect justification for investment.Whether you're directly involved in pharmaceutical technology implementation or interested in how AI adoption affects life sciences advancement, this episode provides practical insights on building systems that deliver genuine value rather than just following technological trends. Connect with Sebastian on LinkedIn to continue the conversation.________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textWhy do we wait until we're severely unwell before seeking help? In this thought-provoking episode, I'm joined by Eva Papadopoulou, a mental health professional and expert in digital and AI-enabled healthcare solutions, to explore the transformative potential of preventative mental healthcare.Eva reveals the stark reality of our current healthcare systems - less than 10% of budgets are allocated to prevention, despite evidence showing preventative approaches lead to better outcomes and cost savings. Using dental care as a compelling example, she illustrates how cultural shifts can transform how we approach healthcare. "We take care of our mind and body before it breaks, not after," Eva explains, offering a vision where mental wellbeing is nurtured proactively rather than repaired reactively.We delve into key areas ripe for preventative intervention, including youth mental health (with most conditions developing before age 25) and workplace wellbeing, where burnout and absenteeism cost businesses billions annually. Technology emerges as a powerful enabler through apps, wearables, and AI systems that can detect early warning signs and deliver personalized support at scale. Eva emphasizes that successful health tech must be co-designed with users and integrated seamlessly into clinical pathways, while better health education is essential to help people interpret their health data meaningfully.The conversation culminates with Eva's powerful vision for healthcare's future: shifting from short-term thinking to long-term investment that prioritizes prevention over crisis management. "Invest in the future instead of firefighting in the present," she urges, inviting listeners to imagine a society where understanding and maintaining mental wellbeing becomes as routine as brushing our teeth. Connect with Eva on LinkedIn to continue this important conversation about transforming healthcare through prevention.________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textRob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.• Current market uncertainty and investment challenges in biotech, especially for rare disease research• Approximately two-thirds of clinical trial processes add no value and aren't required by regulations• Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients• Companies often treat development phases as "islands" rather than planning for commercial success from the beginning• Rare disease economics require greater efficiency since development costs must be recovered from much smaller patient populations• Reviving shelved drug candidates represents a potentially valuable opportunity• Patients should have greater input in trial design and outcome measures that matter to them• Better communication between sponsors and regulators could significantly improve drug development________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textJonathan Hill takes us on a fascinating journey through the cutting-edge world of DNA sequencing and its revolutionary potential for early disease detection. As both an academic professor at Brigham Young University and co-founder of Wasatch BioLabs, Hill shares how third-generation sequencing technologies are transforming our ability to identify diseases years before symptoms appear.The conversation centers on a groundbreaking approach using native methylation calling—a method that identifies specific chemical modifications to DNA—to detect neurodegeneration in conditions like Alzheimer's and Parkinson's. Hill explains how these diseases damage the brain for up to a decade before symptoms emerge, creating a critical window where treatment could be most effective. By detecting the unique methylation signatures of dying neurons from cell-free DNA in the bloodstream, Wasatch BioLabs' technology aims to revolutionize diagnosis and treatment monitoring.What makes this platform particularly powerful is its versatility. The same technology that identifies dying neurons can be adapted to detect signatures from other dying cell types, potentially offering early diagnostics for autoimmune diseases, various cancers, and other conditions—all from a simple blood draw.Beyond the science, Hill reveals his passion for nurturing the next generation of biotech entrepreneurs. He's created a unique ecosystem at BYU where students with innovative ideas receive the mentorship, lab facilities, and business connections needed to translate academic discoveries into real-world applications. Drawing parallels to the tech boom of Silicon Valley, Hill emphasizes that biotech is experiencing its moment of explosive innovation, though with unique regulatory and infrastructure challenges.The episode concludes with a thoughtful discussion on regulatory hurdles in life sciences and how streamlining these processes—while maintaining safety standards—could accelerate innovation and save countless lives. For anyone fascinated by the intersection of cutting-edge science, entrepreneurship, and healthcare transformation, this conversation offers an inspiring glimpse into the future of medicine.________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textVectors are the unsung heroes of cell and gene therapy—molecular couriers that transport therapeutic genes into human cells to treat disease. But as Alan Griffith, Head of Global Operations at Vector Builder reveals, creating these sophisticated delivery vehicles is far more complex than most realize.Drawing from over a decade of experience developing gene therapies before joining the CDMO sector, Griffith offers rare insight into what makes manufacturing these therapies so challenging. Vector design emerges as the critical yet underappreciated factor determining success or failure. "The fundamental sequence and vector composition itself is so fundamental to manufacturability," Griffith explains, noting how seemingly minor elements can dramatically impact production at scale. This knowledge has evolved painfully over the past decade, with clinical holds and manufacturing failures teaching hard lessons.The relationship between therapy developers and contract manufacturers proves equally crucial. Rather than transactional exchanges, successful partnerships require deep collaboration and shared risk. "Working with a CDMO is like dancing with someone you don't know," Griffith observes, emphasizing how Vector Builder aims to understand diseases and vector compositions thoroughly rather than simply executing manufacturing orders.Cost remains perhaps the greatest challenge facing cell and gene therapies. While small molecule drugs might be considered expensive at $10,000 per dose, that figure would be remarkably affordable for gene therapies. Strategies to address this include better vector design to reduce manufacturing failures, more targeted delivery requiring smaller doses, and challenging the "one-and-done" assumption that has proven more complex in reality as expression often diminishes over time.Looking ahead, Griffith sees complementary roles for both viral vectors and emerging non-viral delivery systems like lipid nanoparticles and exosomes. He predicts viral vectors will continue to dominate certain applications for decades due to their unmatched effectiveness, while non-viral approaches may offer manufacturing advantages and potentially lower costs.Cell and gene therapies are revolutionary treatments with vectors serving as "molecular couriers" that deliver genetic materials to target cells, but manufacturing these therapies presents significant challenges in scaling, cost, and regulatory compliance.________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textThe untapped potential of electronic health records has long been recognized in clinical research, but extracting meaningful insights from this treasure trove of data has remained an elusive challenge—until now.Vish Srivastava, founder of Century Health, reveals how artificial intelligence is revolutionizing real-world evidence by unlocking critical patient data trapped in EHRs. Traditional patient registries that once took a decade to amass just 1,000 patients can now be created with unprecedented efficiency through AI-powered data extraction. The breakthrough lies in advanced language models that can interpret unstructured clinical notes, transforming them into structured, analyzable data points while maintaining patient privacy.This technological revolution has profound implications across the drug development lifecycle. In multiple sclerosis research, analyzing 10+ years of longitudinal patient data has illuminated disease progression patterns beyond relapses, informing the next generation of treatments. For approved medications like GLP-1s, real-world evidence is uncovering potential applications in conditions ranging from metabolic disorders to neurodegenerative diseases, potentially fast-tracking label expansions that would traditionally require years of additional clinical trials.The vision is transformative: reducing the $2.6 billion, 12-year journey of drug development to a fraction of that time while ensuring treatments reach the right patients faster. While Century Health initially focuses on gastroenterology, neurology, and rheumatology in the US market, the underlying technology promises to revolutionize clinical research globally. As Vish notes, "It feels like we can create dramatically better outcomes for patients if we can just make the data that's already collected from their care accessible and actionable."________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textJoin us for a conversation with guest Shelli Pavone, co-founder of Inlightened, to uncover the untapped potential of diversity in clinical trials. Discover how historical mistrust, structural barriers, and exclusion criteria continue to hinder diverse patient recruitment. Shelli sheds light on the transformative impact inclusive trials have on scientific integrity, safety, and the generalizability of results. By embracing diversity, not only do we align with regulatory expectations, but we also pave the way for innovation and trust in our healthcare systems. This episode promises to expand your understanding of why diversity in trial participation is a scientific necessity rather than just a moral obligation.Explore the importance of diversifying clinical trial staff to boost trial success and enrollment rates. Shelli discusses breaking the mold of traditional investigator homogeneity by incorporating minority physicians, which fosters trust and enhances trial outcomes. Her insights into the creation of Inlightened reveal a passion for revolutionizing access to healthcare expertise, championing diverse voices, and pushing for equitable innovation. Uncover how Enlightened endeavors to challenge the constraints of conventional investment patterns and encourages the industry to embrace ideas that promise greater societal benefits. This episode covers: • Exploration of historical mistrust in clinical trials• Challenges faced in diversifying patient recruitment• Benefits of having diverse voices in clinical research• The FDA's evolving stance on diversity in clinical trials• The role of diverse investigators in influencing patient enrolment• Strategies to reduce barriers and increase participation• Shelli's journey and passion for healthcare innovation• The overarching need for change in the clinical trial landscapeShelli Pavone: https://www.linkedin.com/in/shelli-pavone-a729b2/ Inlightened: https://getinlightened.com/ ________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textIn this episode we dive into Brain-Computer Interface (BCI) technology, where the brain's faint signals are harnessed to create life-changing applications. Andreas Forsland and Greg Johns emphasize the importance of community-driven innovation, guided by the Brainiac Council—a unique assembly of patients, caregivers, and experts. This collaborative approach ensures that the solutions developed address real-world challenges, improving communication and independence for those with severe impairments. The discussion also highlights a groundbreaking clinical trial with the University of Waterloo, showcasing how AI-enhanced devices can reduce social isolation and enhance quality of life.We also cover:• Importance of user feedback in product design • Communication technology for ALS, Parkinson's, and more • The regulatory challenges of medical device development • Integrating AI to improve user experience and interaction • Future vision for accessible health technology • Ethical considerations surrounding brain-computer interfacesGuests:Andreas Forsland: https://www.linkedin.com/in/andreasforsland/Gregg Johns: https://www.linkedin.com/in/gregg-johns-product-leader/ ________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textThis episode reveals alarming statistics about patient access to clinical trials, highlighting that only 3% of patients currently have access to participate. Our guest, Jill Pellegrino, CEO of Auto Recruitment, shares innovative strategies to engage the other 90% of the patient population and discusses the importance of digital advertising, pre-screening, and patient support in the recruitment process.• Discussion on the low percentage of patient access to clinical trials • Barriers for physicians and research sites in patient enrollment • Strategies to engage patients through digital advertising • Importance of pre-screening for trial eligibility • The role of EMR technology in improving recruitment • Ensuring patient engagement post-initial interest • Feedback and response from clinical trial sites • Future plans for wider patient access to clinical trials • Emphasis on patient-centric approaches in clinical research This week, if you have any questions about Auto Recruitment or want to connect with Jill, visit https://www.autorecruitment.com.________Reach out to Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textWhy has SAS been the cornerstone of clinical trials for decades, and what is causing the shift to R now? Join us on "Transformation in Trials" as we explore this pivotal transition with Sunil Gupta, a seasoned programmer who has navigated both worlds. Sunil elaborates on SAS's long-standing dominance due to its robust programming capabilities and ease of use for FDA reviewers. However, the landscape is changing as R garners attention for its graphical prowess and collaborative potential. The conversation highlights the growing trend of new graduates versed in R and Python, which alleviates the shortage of SAS programmers and signifies a modernization wave in clinical trials, ultimately aiming to accelerate drug development.Our discussion takes a deep dive into the collaborative spirit driving this transition, particularly through initiatives like Pharmaverse. This specialized extension of Tidyverse is designed to optimize clinical data workflows within the pharmaceutical industry. Sunil shares insights into how clinical programming is evolving, focusing on standardized data models and the unification of CDISC standards. The conversation underscores the importance of collaboration and resource sharing, allowing organizations to tackle complex challenges efficiently and improve patient outcomes while adapting to R's open-source environment and its growing acceptance in pharmaceutical submissions.Transitioning from SAS to R is not just about adopting a new tool; it's about mastering new skills and embracing change. Sunil discusses the challenges he faced when learning R, from understanding its functional approach to navigating intricate syntax. He offers personal anecdotes that reflect his journey and the broader industry shift, emphasizing the importance of validation processes and resource optimization. As we conclude this episode, we express gratitude for the platform to discuss these transformative changes and invite listeners to engage with us on future topics, continuing to share success stories that inspire more organizations to embrace the power of R.________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a textPrepare to transform your understanding of vendor oversight in clinical trials as we welcome Jessica Cordes, a senior consultant and trainer at the Clinical Excellence Consultancy. Jessica brings her wealth of experience to highlight the intricate responsibilities that sponsors must navigate when outsourcing tasks. Our conversation promises to equip you with insights on maintaining control, mitigating risks, and leveraging technology like AI and machine learning to future-proof your oversight strategies.Metrics are more than numbers—they're a lifeline in managing vendor relationships. Learn how robust oversight can impact patient safety and compliance metrics. We'll explore the necessity of tailoring KPIs to specific risks and the importance of a risk-based approach that starts from vendor selection and continues through ongoing management. Jessica's emphasis on creating a standard operating procedure framework will guide you in ensuring consistency and accountability in sponsor-vendor interactions.Effective communication is the cornerstone of successful clinical trials. Through personal anecdotes and practical advice, we tackle the challenges of unit-based contracts and introduce milestone-based contracts for enhanced efficiency. From vendor selection to team building, Jessica shares her consultancy insights tailored for small and mid-sized biotech and pharma companies. We also consider the upcoming ICH E6 R3 guidance, emphasizing fit-for-purpose procedures in quality management systems, all while advocating for improved collaboration among stakeholders to enhance patient-centricity and accelerate drug development.________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a Text Message.How do you navigate the complexities of manufacturing cell and gene therapies that are tailored to individual patients? Find out as we sit down with Dr. Bruce Levine from the University of Pennsylvania to unpack the intricacies of clinical research in this groundbreaking field. From the unique emphasis on chemistry, manufacturing, and controls (CMC) to the logistical hurdles of sourcing and modifying patient-derived cells, Dr. Levine offers an expert's perspective on the challenges and advancements that set these therapies apart from traditional drugs. We also shine a light on the vital role of the International Society for Cell and Gene Therapy in driving forward these innovative treatments.In another riveting segment, we delve into the recent FDA investigation into cases of T-cell malignancies following CAR T-cell therapy. With data gleaned from voluntary reporting databases, we scrutinize causality, immortal time bias, and the need for improved reporting standards. Dr. Levine shares his thoughts on the importance of thorough patient follow-up and effective communication of risks and benefits. We also explore the evolution of cell and gene therapy, tracing Dr. Levine's journey from his early days in immunology research to his pivotal role in shaping the field. This episode is a must-listen for anyone interested in the dynamic and ever-evolving world of cell and gene therapy.________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Send us a Text Message.What if re-engaging with your purpose could revolutionize your job satisfaction and mental health? Join us for our conversation with Jill Donahue, a leader in life sciences whose personal journey through psychology, behavioral science, and a profound personal tragedy has fueled her mission to improve communication and trust within the healthcare community. Jill opens up about how these experiences led her to create initiatives like her book "A Dose of Inspiration" and the Aurora Project, both aimed at fostering a deeper sense of purpose among life sciences professionals.Step into the world of Johnny, a shuttle bus driver in Phoenix, who discovered how focusing on spreading happiness could significantly transform his work experience and income. This inspiring tale serves as a powerful reminder that a purpose-driven mindset can make a difference in any role, from healthcare to pharma and beyond. Jill and our hosts discuss practical strategies for connecting with your "why" and engaging audiences during presentations through personal motivations and stories, highlighting how genuine connections can enhance both professional and personal experiences.The conversation shifts to the pharmaceutical industry's much-needed transformation towards patient partnership. Jill passionately advocates for a shift from product-centric to patient-centric narratives, emphasizing the importance of presenting treatment options and building expertise in specific disease states. This approach, she argues, not only improves patient care but also makes the role of pharma representatives more fulfilling. Tune in to hear Jill's excitement about her book, "A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders," and her dream of igniting a sense of purpose in everyone within the industry.Notes: A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders can be found on Amazon or as a free download at www.excellerate.ca/freebook More information about The Power of Purpose can be found hereJill can be reached here on LinkedIn________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

When nine out of ten clinical trials don't cross the finish line, it's time to ask tough questions and seek innovative answers. That's exactly the journey we embark on with Vinodh Balaraman from KolateAI in our latest podcast episode. Together, we unravel the complex knot of challenges that lead to clinical trial failures, from flawed study designs to enrollment obstacles and the unexpected curveballs thrown by the approval of competitor drugs. But it's not all doom and gloom; we shine a light on the potential of AI to bring about much-needed predictive capabilities, paving the way for trials that are as efficient as they are effective.Ever wondered how big data and predictive analytics could be the game-changers in drug development? Our conversation takes a deep dive into the role of AI in forecasting how patients will respond to treatments, potentially transforming the hit-and-miss nature of clinical trials into a targeted approach. We discuss the transformative power of a SaaS business model and shared knowledge bases, considering how they could overhaul the pharmaceutical landscape. Despite the industry's tentative steps toward data sharing, we explore the gradual shift as medical professionals begin to wield these cutting-edge tools to make smarter, data-driven decisions.Bringing a dose of humanity to the tech talk, I share my personal motivation stemming from a family member's battle with rheumatoid arthritis—a catalyst for my commitment to pushing the envelope in clinical development. The episode concludes with a reflection on how AI stands on the brink of revolutionizing medical affairs and real-world studies, but is often met with skepticism. By fostering a culture open to change and innovation, we envision a future where clinical trials become more successful and efficient. Join us as we discuss the landscape of trials and the untapped potential that KolateAI brings to this critical field.Guest: Vinodh Balaraman________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Navigating the tumultuous sea of inflammatory bowel disease (IBD) is no small feat, and Ariadna Maso of Sanno Health is our compass on this voyage. As the mastermind behind a company that's reshaping how we understand and manage gut health, Ari shares her intimate understanding of the patient's struggle, from the stinging uncertainty of diagnosis to the often overlooked psychological toll. Our conversation goes beyond the standard medication narrative and into the realm of holistic care, where anti-inflammatory diets and mental health support take center stage. Ari's insights into ongoing research illuminate a path for integrating these lifestyle modifications into patient care, offering a beacon of hope for those navigating these often-rough waters.When it comes to personalizing patient care, digital biomarkers are the wayfinders charting a course through the previously uncharted territories of healthcare. But the journey is fraught with challenges: data diversity, operational hurdles, and the sheer volume of information from tools like wearables. In this episode, Ariadna navigates us through these operational storms, detailing how Sanno Health evolved from an app into a comprehensive platform that's not only tracking patient health but is actively engaging them in their treatment. We also probe into the stark disparities between industry perceptions of patient-centric care and the realities patients face, unveiling the transformative potential of incorporating patient feedback directly into clinical trial designs. Join us as we explore the diverse therapeutic landscapes that stand to benefit, including digestive health and the burgeoning realm of women's health, and the far-reaching implications of data-driven medical advancements.GuestAriadna Masó________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we sit down with Erini Schlosser, CEO of Dyania Health, and chart the pioneering advancements in large language models within healthcare. This episode promises to reveal how the shift from simple entity recognition to sophisticated reasoning models has revolutionized drug discovery and the curation of electronic medical records, all while unpacking the challenges of data privacy, computational demands, and the hunt for specialized AI talent. Discover the fusion of technology and medicine where the collaborative potential for real-world data utilization in evidence-based studies emerges as a beacon for innovation amidst the complexities of modern clinical trials.As we explore the parallels of AI training to medical education, you'll be enthralled by stories of AI models undergoing meticulous fine-tuning by our in-house physicians, echoing the rigorous journey of medical residents. Irene lifts the veil on her own path, which led from a lineage steeped in medicine, through the worlds of biochemistry and investment banking, to the groundbreaking integration of NLP into healthcare at Dyania Health. Our conversation shines a light on the future of automating clinical research, where AI not only answers but justifies with evidence, promising an unprecedented era in the management and interpretation of medical data. Tune in for an intimate look at the challenges overcome and the milestones achieved in teaching machines to navigate the intricacies of human health.Guest:Eirini Schlosser ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Uncover how the seamless fusion of wearables with patient data is revolutionizing clinical trials in our latest conversation with Wessam Sonbol, the Founder and CEO of Delve Health. We navigate the transformation from cumbersome paper reporting to the sophisticated use of Patient Reported Outcomes and the continuous insights wearable technology offers. As we dissect the benefits and hurdles of this evolving data landscape, you'll get an insider perspective on the intricacies of managing vast health metrics and setting benchmarks for impactful analysis. Plus, Wessam shares his knowledge on the reliability and strategic employment of wearables in clinical research, offering a glimpse into how these devices are altering the way we approach health monitoring.In our discussion, the concept of 'wearables as a service' emerges, a trailblazing model crafted by Delve Health to elevate the clinical study experience for both patients and researchers. Wessam delves into the rigorous process of selecting wearables that align with trial goals, sharing how gadgets like Fitbits undergo efficacy evaluation. Be prepared to discover how innovations like automated compliance and concierge teams are mitigating study site burdens and boosting data quality. We also tackle the broader spectrum of challenges and advancements in clinical research, contrasting the swift advancements in wearable tech with the methodical progress of drug trials. Join us to envision a future that prioritizes patient-centric care, reduced tool burden, and heightened automation, and don't miss Wessam's call to action for ongoing dialogue that aims to reshape the patient experience in the health and life sciences arena.Guest: Wessam Sonbol ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Unlock the secrets of clinical trial design with industry experts Pierre Colin and Boaz Adler as they join us for a deep dive into the early-stage planning that shapes the future of pharmaceuticals. They provide a  look at the collaboration between clinicians, statisticians, and regulatory experts that's critical for determining the right patient populations, dosages, and study endpoints. With their guidance, we explore how statistical software and scenario planning play pivotal roles in estimating patient numbers, study durations, and costs, transforming clinical trial design into a fine art.As we navigate through the evolution of statistical methods, our guests share their insights on the need for adaptability in clinical trial designs, especially in areas like oncology with unique endpoints such as overall survival. They spotlight the importance of cross-company collaborations and direct FDA discussions in driving innovations. The conversation also illuminates the ever-growing contributions of R-coding, a testament to the individuality of each study, allowing for customized and cutting-edge approaches to trial design.To wrap up, we spotlight the dynamic landscape of drug development where biostatistics paves the way for groundbreaking designs. Our guests emphasize how feedback from scientific communities influences new methodologies, shifting the focus from traditional success measures to concepts like assurance and power in the promising zone. They also highlight the invaluable role of Bayesian designs, as exemplified by COVID-19 vaccine trials, in ethically accelerating drug development. As we close, remember that this field is ripe with diverse opportunities, and we invite you to reach out with your curiosities and follow-up questions. Join us for this episode that's not just about the science of trials, but the transformation they undergo, ensuring the journey of drug development continues to revolutionize patient care.Guests:Pierre Colin: https://www.linkedin.com/in/pierre-colin-11139028/Boaz Adler: https://www.linkedin.com/in/boazadler/________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Embark on a journey through the dynamic landscape of clinical trial outsourcing with Jason Gubb, the co-founder of ClinOps Clarity and Emergent Teams. As we navigate the historical shift from predominantly in-house operations to the intricate web of external partnerships, Jason sheds light on the critical decision-making processes that shape the pharmaceutical and biotech industries. Grapple with the challenges and opportunities presented by R&D budget constraints and learn how emerging biotech firms are steering through fluctuating funding currents. Discover a world where the right choice of vendors can make or break a clinical trial, and how companies balance the scales of internal project management and external collaboration.With Jason's sage guidance, gleaned from his tenure at GSK and his entrepreneurial ventures, we dissect the artistry behind cultivating successful clinical trial partnerships. He shares insights on the transformative effects of smart decision-making and the vigour of challenging established practices while ensuring that every partnership is rooted in open communication and shared goals. Jason also illuminates the impact of a patient-focused ethos and addresses the nuances between co-creation and mere collaboration. So tune in to expand your understanding of the pivotal role that culture and relationships play in shaping the outcomes of clinical trials and to witness the emergence of alliances that are as resilient as they are innovative.________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

In this conversation with Sam Whitaker, we  delve into the pivotal issues faced by underrepresented groups—particularly those from lower-income backgrounds—highlighting the disparity in current demographics and the consequences it bears on the reliability of drug efficacy and safety data for diverse populations. We go beyond the surface to examine the complexities surrounding compensation for trial participants, debunking the myth that stipends serve as an incentive and instead revealing the net financial loss many endure. With Sam's expertise, we explore why the current compensation structures pose significant barriers for those in lower-income brackets.Sam Whitaker's insights prompt us to question the ethical responsibilities of Institutional Review Boards (IRBs) in safeguarding participant welfare, particularly in terms of payment evaluation. The conversation scrutinizes the pressing need for standardized compensation practices, emphasizing the potential financial harm and barriers these present to willing participants. Our discussion raises awareness about the delicate balance between the pursuit of scientific knowledge and the imperative of ethical consideration in the realm of human testing.Lastly, we shine a light on the legislative efforts aiming to dismantle the financial hurdles that deter diverse participation in clinical trials. Tax implications for low-income participants and the risks to their welfare benefits take center stage, with bipartisan support emerging as a beacon of hope in the push for reform. Sam shares the impactful work being done through Mural Health, including the Portrait Project, which seeks to humanize and democratize the clinical research process. Join us to understand how these initiatives are not just transforming patient involvement, but reshaping the landscape of clinical trials for the betterment of all.Guest:Sam Whitaker Mural Health________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Boaz Adler from Cytel's Software Division. This episode promises to illuminate the intricacies of trial design through the lens of Monte Carlo simulation, revealing how this potent approach crafts trials resilient to a myriad of scenarios. Boaz delves into the pivotal roles of interim monitoring and strategic market positioning post-trial, offering a masterclass in the art of clinical trial conception that withstands the test of uncertainty.As we navigate the vast landscape of clinical trial simulation, the topic of scale takes center stage. The conversation orbits around pioneering software platforms like Solara and East, which are reshaping trial design by integrating a kaleidoscope of variables and uncertainties. This episode pulls back the curtain on the potential of cloud computing to revolutionize simulations, providing a glimpse into the future where clinical trials are executed with unparalleled speed and precision. With Boaz' expertise, we ponder the industry's readiness to trust probabilistic outcomes and how regulatory bodies are warming up to the simulation-based approaches that these software platforms enable.Finally, we bridge the gap between biostatistics and market access, highlighting the increasing influence of health outcomes research on clinical trial design. The discourse delves into the balancing act of incorporating quality of life measures for regulatory and reimbursement decisions, the finesse required to blend standard software with bespoke coding, and the imperative of enhanced inter-departmental synergy. My own path to life sciences underscores the episode's reflective tone, leading to a broader examination of Cytel's extensive contributions to the field, from their roots in Monte Carlo simulation software to a comprehensive suite of services that spans the full spectrum of statistical programming and evidence-based research. Join us for this enlightening episode to gain an insider's perspective on the dynamic confluence of biostatistics and pharmaceutical innovation.Guest: Boaz Adler________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Ever wondered why the life sciences industry is stuck in redundant vendor qualification processes? Picture an organization where quality is designed rather than inspected. Yes, it's possible and we're about to paint that picture for you in this stimulating conversation with our guests, Dele Babalola and Rani Naik. They've got their fingers on the pulse of the GxP space and are ready to share their insights on the pressing need to evolve from redundant processes. Pay attention as Rani unfolds her unique vision for an agile, phase-appropriate quality organization. Imagine a world where vendor qualification is not a daunting task but a streamlined process. We got you thinking, right? Dele and Rani join us to unravel this concept further. It's all about being proactive, focusing on effective oversight, and perhaps venturing into the world of pre-approved vendors. From discussing the role of certification bodies to emphasizing the significance of a proactive approach, we've got this topic well covered. Enter the world of vendor management where challenges are like a complex puzzle waiting to be solved. This is where Dele and Rani's expertise shines as they shed light on transparency, collaboration, and the risk-based approach. Here's a plus - they also detail the potential value of remote audits and the importance of having an internal individual who can ensure clear process flow. As we wrap up, we can't help but yearn for a more innovative industry that's ready to take leaps. You won't want to miss this candid conversation.________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Get ready to learn about clinical trials operations from an expert. This episode is an opportunity to learn all about the essential aspects of managing such trials and the core role of contract research organizations (CROs) in the process. We have the privilege of introducing Becky Baggett, Associate Vice President of Project Delivery at Rho, who unravels the complexities of clinical trials for us. She not only lays out the distinct stages and components of a clinical trial but also enlightens us on the crucial collaboration between the sponsor and the CRO, the importance of clinical research sites, data management, and project management. She underscores the absolute necessity of establishing solid relationships, trust, and experience in this highly controlled and regulated field.As we navigate further, we plunge into the thrilling and demanding world of technology in clinical trials. This part is a trove of information on how technology can streamline trials and why it's crucial to tailor technological applications to the specific needs of therapeutic areas. This episode is not just about information, but also about engaging in a thought-provoking discussion, where we examine the subtleties of conducting trials across different therapeutic areas. We end on a note of aspiration, echoing the collective wish for increased funding in the industry, which could potentially fast track more life-saving medications from lab to market. GuestBecky Baggett________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Ever wondered what goes into designing a modern, adaptable, and inclusive lab space? Join us as we uncover the intricacies of laboratory planning with architect and lab planning leader, Marilee Lloyd. Marilee takes us behind the scenes of designing new research labs, divulging the importance of flexibility, adaptability, and the use of modular benching. She sheds light on the unique challenges and considerations of modernizing older labs, while emphasizing the impact of thoughtful lab design on achieving clinical outcomes.We also engage in a lively discussion on sustainable and inclusive lab design with our  guest. Marilee's passion for diversity in the life sciences industry and her dedication to creating environmentally-friendly and welcoming lab spaces is truly inspiring. From reducing air changes and utilizing high-performance fume hoods to fostering inclusivity with elements of nature and thoughtful design, Merilee provides a unique perspective on lab planning. Guest:Marilee Lloyd ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Ever wondered about the science behind a simple cough? What if we told you that a cough is not as simple as it seems and AI technology could revolutionize how we perceive it? Come along as we host Dr. Peter Small, acoustic epidemiologist and Chief Medical Officer of Hyfe, who enlightens us on the complexity of measuring coughs in clinical trials. Hear how traditional cough assessment methods are falling short and the challenges the FDA faces when validating new cough-suppressing medications. Furthermore, we discuss the severe impact of chronic cough on individuals, exacerbated by the COVID-19 pandemic, and how acoustic AI offers a unobtrusive and privacy-preserving solution for cough counting. Imagine a future where cough monitoring becomes as routine as step counting. In the second half of our chat, Peter shares insights on the potential of acoustic diagnostics in revolutionizing cough treatment. Hear about a promising digital therapeutic for chronic cough, designed to reduce cough frequency, and the scarcity of effective cough treatments in today's medical landscape. From wellness apps to dedicated watches and SDKs for various devices, we discuss different forms of cough recognition technology, setting the stage for a future where technology and healthcare converge in fascinating ways. Guest: Dr. Peter SmallHyfe ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Join us in a conversation with Nechama Katan, as we investigate the  world of generative AI in life sciences, a realm where technology meets business, and where Nechama, an expert in innovative data in the clinical space of life sciences, will guide us.We're taking a deep dive into the ever-evolving realm of technology in life sciences. We'll take a look at the shift from standalone to integrated tools, and how generative AI is influencing the distribution of labor in life science companies. We'll also explore the potential uses of generative AI in data summarization, and how it could disrupt the traditional role of programmers in clinical trials. Nehamah will share her experiences with chat GPT, Amazon product reviews, Grammarly, and Databricks AI Assistant, shedding light on how generative AI is being implemented in clinical trials and data analysis.Finally, we will explore technology's significant role in data analysis. Nechama envisions a future where data is readily accessible to everyone seeking answers. She believes generative AI can help us verify random facts and enhance exploratory data analysis. She'll also share insights on how providing the right context to AI can enhance our understanding of the data in front of us. Tune in for this insightful discussion and be sure to reach out to Nechama for any queries or assistance you may need with a complex problem. Guest: Nechama Katan________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

What if a pharmaceutical company can be deconstructed and re-assembled in a new configuration? This is already happening in cell and gene therapy manufacturing. Join us for an enlightening conversation with Jason Bock, the founder and CEO of CTMC, who has been at the forefront of this intersection between clinical research and manufacturing. Discover the unique challenges of setting up a manufacturing network for autologous cell therapies and how this relationship between clinical and manufacturing sites differs from traditional methods. Jason shares his journey of moving to MD Anderson Cancer Center, setting up a biotech firm, and transforming the supply chain, thereby expediting product development.Imagine the thrill of cell therapy advancements and the potential for cures in a single dose! Uncover how the trailblazing minds at CTMC and MD Anderson have submitted six INDs in the span of just 18 months. Half of these are MD Anderson invented therapies, while the rest are biotech invented products. Alongside these exciting developments, we also delve into the implications of such revolutionary treatments on the healthcare system. Understand the challenges that lay ahead in terms of making these potentially curative treatments widely accessible. Tune in for this riveting discussion on the transformation of healthcare, offering a glimpse into the future of medicine.Guest: Jason Bock________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

How is the pharmaceutical and biotech industry changing in the current financial climate? Our guest today, Ryan Keane, founder and CEO of Korio, shines a bright light on these subjects and more. This discussion is an exploration of our current healthcare landscape, dissecting the challenges companies face as they introduce new technology, the sudden shift in the vendor landscape, and the unexpected destruction of value in biotech due to companies discarding or divesting their assets.We don't just stop at the surface. Ryan takes us deep into the complexities of customizing Interactive Response Technology (IRT) systems in clinical trials, highlighting the crucial role of education for both buyers and industry employees. We tackle the challenges of communicating complex information to patients and the need for creating reproducible and scalable processes. The conversation veers into the often misunderstood realm of clinical trial supply, the need for a no-code environment, and the importance of having technologically savvy folks who comprehend all the elements. Guest:Ryan Keane ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Ready to lift the lid on the untapped potential of open-source technology in clinical trials? Strap in for a fascinating journey with our guest Lionel van Holle, the founder of Open Source PV. We'll unveil the transformative power of open-source tech in the life sciences industry, including its innate transparency, parallel development capabilities, and cost-effectiveness. Lionel shares insights into the diversity of SAS, R, and Python programmers involved in this field, revealing how the open-source revolution is just around the corner.The collaboration between code and pharmacovigilance is changing the game, and we're excited to share this revelation with you. Tune in as we navigate the complexities of finding the right code packages and understand the nuances of search engine keywords. We also uncover the tremendous impact of the FDA's move towards open-source data and algorithms, highlighting the future of industry-wide collaborations. Concluding our discussion, we delve into the promise of machine learning and automation in medical writing, demonstrating how tech is poised to interpret data and create automated reports, potentially revolutionizing the way we see medical documentation. Join our enlightening conversation and discover the next frontier in life sciences.Guest: Lionel Van Holle________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Ever wondered how the healthcare industry can leverage the power of marketing? Join us as we unravel the mysteries of programmatic marketing with the CEO and founder of Doceree, HJ. He takes us through the innovative platform that reshapes how messages are targeted to healthcare professionals. From reaching physicians, nurses, and pharmacists with personalized messages to rolling out patient savings programs, the benefits are limitless. All while staying compliant with data privacy and security guidelines. Buckle up for a deep dive into the world of automated marketing as HJ shares how their multi-tenant model disrupts the traditional process of segmentation.But that's not all. Shifting landscapes, we get a taste of global pharmaceutical markets with HJ, a physician turned advertising expert. Navigating the choppy waters of language barriers and siloed data, HJ emphasizes the importance of market understanding before making that leap. He delivers a raw, unfiltered view of his journey in the advertising space and the critical role of market feedback in propelling growth.  Here's your chance to gain a fresh perspective on the intersection of healthcare, marketing, and technology.Guest:Harshit Jain ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Join us in a fascinating conversation with our special guests, Richard Nkulikiyinka, as we unravel how endpoints in trials are transforming and the significant role they play in determining trial efficiency. We also delve into innovations in oncology endpoints and discuss the challenges and opportunities in cardiovascular trials. Tune in as we explore the use of composite endpoints in heart failure trials and exciting functional endpoints that are potentially leading the way for approval studies.We took a deep dive into the critical impacts of trial design and data collection on entire trial enterprises, emphasizing the importance of prospective validation. Richard shared intriguing insights about the changing landscape of trial design and its ripple effect on the industry. He gave an in-depth analysis of sodium-glucose co-transporter inhibitors and the revolutionary changes they brought to the standard of care through a series of trials. You wouldn't want to miss their take on the advantages of umbrella and basket trials and the essential role collaboration plays for their success.In this riveting discussion, Richard also illuminated the transformative power of innovation and collaboration in clinical trials. We delved into the thrilling potential of cross-company collaboration in investigating the same patient population and the possible role of impartial brokers. Richard also sheds light on how AI and technological advancements could enhance clinical trial outcomes. Listen as they dissect the potential of AI in imaging, its role in streamlining assessment processes, offering real-time feedback, and reducing the burden on specialists. As we wrapped up, we examined how machine learning could make clinical trials more cost-effective by automating the adjudication of events in cardiovascular trials. This enlightening conversation is a treasure trove of insights into the dynamic world of clinical trials. ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Understand the complexities of clinical trial design from a seasoned expert. We speak to our esteemed guest, Richard Nkulikiyinka , a senior leader in clinical development. Richard illuminates the often-misunderstood world of trial design, from setting objectives and identifying target populations to the nitty-gritty like data collection, visit schedules, and maintaining quality. The spotlight shines on patient-centric approaches, as Richard persuasively argues for designing trials that are more patient-friendly without sacrificing quality.As we go deeper into the conversation, we reveal the intriguing process of creating and accepting endpoints for various diseases. Richard presents a compelling case study of heart failure trials, debunking the notion that traditional endpoints are always the best fit. He illustrates how a novel endpoint for counting all hospitalizations was innovatively developed and accepted by health authorities — a process that holds potential for other diseases reducing exercise capacity. But it's not all about the technicalities. We also underscore the crucial role of collaboration in developing endpoints. To illustrate this, Richard  shares his experience charting the benefits of pre-competitive collaboration between industry partners, academic institutions, and health authorities. We also navigate the challenges of innovating clinical trials, discussing the constraints of mega trials and escalating costs, and the collective effort needed to accelerate the development of new therapies. Get ready to reimagine the future of clinical trials with this enlightening discussion!________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Join us as we talk to Pradeep Sacitharan, a serial dropout turned award-winning scientist. Starting life as a war refugee and working in London bars, Pradeep's life took a radical turn following a near-death experience, propelling him into the world of drug development. He navigates us through his fascinating journey in the biotech world, recounting his trials and triumphs in the field.Ever considered that academia might be flawed? Pradeep exposes the cracks in the academic system, expressing the need to revamp the current structure and invest more in budding talent. He shares his unique approach to experimentation, emphasising the power of learning from rejections. As he delves into his own experiences, he offers valuable insights to help young researchers navigate the often daunting world of academia.But Pradeep's insights don't stop at academia. He explores the relevance of practical learning, neurodiversity, and talent identification. Plus, he sheds light on the fascinating and often complex world of biotech funding, helping us understand the important details often overlooked. Pradeep's story is not just about his own journey, but it also serves as a guide for anyone looking to carve their own path in the world of science and beyond. Tune in and learn from his unique perspective on the changing landscape of biotech, academia, and talent management.Guest: Pradeep Sacitharan ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Ever imagined the immense potential that decentralized clinical trials (DCTs) could unlock for patients and sponsors? This week, we're going on a deep dive into the world of DCTs with our esteemed guest, Ewa Lindqvist, a trailblazer in this space. Brace yourself for an enlightening conversation about how DCTs are paving the way for increased access to new treatments and real-time data for physicians, all while slashing costs and inefficiencies.Resistance to DCTs, stemming from technology fears and competency gaps, is a significant hurdle. However, our discussion with Ewa sheds light on how regulators have transformed into allies in this journey. We also unveil Thread, an innovative app poised to streamline DCTs, with its impressive capacity to monitor compliance, safety, efficacy, and much more. So, if you've been apprehensive about DCTs, it's time to shed those fears!In our final segment, we touch on the pivotal role of convenience in clinical trials. Learn how Thread is leveraging technology to synchronize wearables and EDC data, thus driving efficient clinical trial processes. Also, we explore the integral role of patient advocacy organizations in ensuring DCTs are offered to patients. This conversation promises to revolutionize your understanding of clinical trials and the extraordinary potential of decentralization. Tune in and get ready to be amazed.Guest: Ewa Lindqvist________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Prepare to uncover the transformative potential of open source software in the pharmaceutical industry! Our distinguished guest, Katja Glass, an influential open source ambassador, joins us on this enlightening journey. We'll explore the rising popularity of open source solutions in the pharmaceutical industry, its myriad benefits, and the profound impact of sharing tools, processes, and software.Turn up the volume as we unravel the advantageous features of the Open Study Builder. This unique tool has not only helped pharma companies in embracing automation but also presents an innovative approach towards modern metadata repositories. We take a closer look at how its  properties facilitate creating protocols, bringing a refreshing twist to the traditional processes. As we conclude, we ponder over the future prospects of the Open Study Builder, the implications and the exciting opportunities for tech vendors to engage with the Open Study Builder ecosystem. Katja shares her perspectives on the possible transformations. Tune in as we draw parallels between the pharmaceutical industry and other sectors and explore what lessons can be learned from their uptake of open source. So, buckle up and get ready for an intriguing conversation revolving around the changing dynamics of trials in the pharma industry!Guest:Katja Glass________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Imagine being given a shot at a cure before it's even approved. That's the fascinating world of expanded access programs for unapproved investigational interventions that we're exploring today with our esteemed guest, Patti Zettler, law professor and chair of the International Society for Cell and Gene Therapies Expanded Access Working Group. We delve into the history of these programs, the FDA's role in their regulation, and the surge of interest they've seen in the last decade. Ever wondered why a patient would be willing to be a first mover on a yet-to-be-approved drug? Patti provides enlightening insights into this unique field.We then delve deeper into the intriguing complexities of expanded access programs within the realm of cell and gene therapy. We navigate through the potential for these programs' misuse by pharmaceutical companies, and the tension between the need for scientific evidence and a patient's desire for early access. The conversation also explores the ethical and legal dilemmas these programs present, the doctor's role, and the challenge of effectively communicating associated risks to patients. We wrap up with a contemplation on the changes we hope to see in the industry. Patti's insights, coupled with our thought-provoking discussion, will leave you with a deeper understanding of this crucial aspect of modern medicine.Guest: Patti Zettler________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Imagine you're on an eight-year journey trying to diagnose an autoimmune disease. Suzaan Sauerman, our insightful guest today, faced this exact challenge. Sauerman, a visionary in female representation in clinical trials, uncovers the persistent gender gap in this field and posits an innovative solution—wearable technology.We dig into the heart of Sauerman's story with a touching account of her mother's heart disease experience, a stark illustration of the gender bias in medical research. Wearable technology, Sauerman suggests, can close this gap, capturing vast data from thousands of women, while offering a more in-depth understanding of female anatomy. Our discussion touches on the potential of these wearables—earables and the like—in health tracking, the need for better design, and the importance of women's involvement in product development.Not to be missed, Sauerman's personal tale of autoimmune disease diagnosis unfolds, setting the stage for a spirited debate on wearable technology's role in accelerating health diagnosis. We push the boundaries of this conversation, exploring how these devices could shape our awareness of health, preventative care, and even alter insurance premiums. Sauerman's passion for empowering consumers, particularly women, with these devices is infectious. Join us as we envision a future where technology seamlessly integrates into our health journey, enhancing our life one wearable device at a time.Reach out to Suzaan Sauerman on LinkedIn________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Let's face it, executive turnover in the life sciences industry is a conundrum. Companies are offering competitive compensation, fostering positive work cultures, and providing opportunities to contribute to meaningful work, yet many executives continue to leave. In our intriguing dialogue with the insightful Federico Grayeb, we delve into why this is happening and how job embeddedness could be a key factor in predicting retention. Grayeb's perspective brings to light the deeper dynamics at play in the industry, such as the abundance of job offers executives receive and the high level of isomorphism, making it easier for them to switch roles within the industry.But there's more to the story than just job offers and industry dynamics. Federico shares thought-provoking insights into how external events – even positive ones like pregnancy or acceptance into a prestigious school – can lead to a departure, regardless of job satisfaction. He also discusses the concept of job embeddedness, a measure of an individual's connection to their job and outside life, and its significant role in forecasting retention. We also explore Grayeb's fascinating work on a tool that assesses job embeddedness and his approach to hiring based on psychological fit. So, join us as we navigate this complex terrain and uncover transformative ideas to tackle executive turnover in the life sciences industry. You wouldn't want to miss it!Reach out to Federico Grayeb via LinkedIn________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Ravi Samavedam, Chief Innovation Officer for Azzur Group, about how on demand clean rooms can transform the business model for biotechs. We start out by exploring what the standard two choices biotech's typically have for clinical trial manufacturing:Building their own infrastructureOutsourcing to a contract manufacturing organizationBoth options have pros and cons. Many of the cons can be mitigated by the third option that Ravi suggests - renting the infrastructure. This enables the biotech to keep control with the manufacturing process and keep experimenting, while avoiding the upfront investment in the infrastructure that may change. We also dive into the compliance of the facilities, and how outsourcing the quality assurance of the facilities themselves can allow the biotech's to focus on the production process and science. Even though the clean rooms for the different companies are in the same facilities, there is no exchange of air or supplies between the rooms - and also limited exchange of ideas between the individual production lines due to confidentiality. As a small biotech it is easy to fall into the trap of going overboard with GMP regulation adherence. And how GMP stamina is necessary to know where to draw the line of sufficient quality. Guest:Ravi Samavedamhttps://www.linkedin.com/in/ravi-samavedam-65a8345/ Azzurhttps://azzur.com/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Leif Kuse, who is Lead Trailblazer of Drug Development Outsourcing Disruption and CEO PHARALL.We speak about group purchasing for biotechs in clinical trials. We start out by exploring how CRO contracting usually happens for biotechs, where clinical trials are typically outsourced to CROs. Biotech outsourcing is especially tricky, because in especially smaller companies, there may not be competencies to handle a sudden increase of people working for the company by adding a partner to the organization.   There are several models for collaborating with vendors - from a turnkey project, where you just “hand over the key” to a vendor, and wait for the results - to a close explorative collaboration, where the partner is basically a part of your organization. We discuss the difference in services and pricing that is on the table for big pharmaceutical companies and biotechs, exploring the dynamics of the market and collaboration models.There is no ideal CRO for a biotech - it all depends on what is needed, and how a collaboration can be established. Leif provides examples of great collaborations between CROs and biotech companies - where processes, culture and contracts all meshed. The patient stands to benefit from successful collaboration between sponsors and CROs. The trials can be executed more smoothly and drugs can make it to market more rapidly.  Lastly we discuss if the pharmaceutical value chain could be decentralized in general, with companies like PHARALL brokering different parts of the value chain into a coherent whole. Guest:Leif Kusehttps://www.linkedin.com/in/leif-kuse-32042411/PHARALLhttps://pharall.de/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Tirrell Payton, Managing Partner at Nooma Group Consulting, about mindset in life sciences. We speak about how there is a disconnect between the level of risk willingness among the top levels in organizations and middle managers. Middle managers are often afraid to make a mistake - and become the “permafrost layer” where change has a tough time to take root. We also speak about how institutional storytelling about past failures in a company can hinder people to try new things. These stories can act as invisible guardrails that limit what can be tried in an organization. Without being actual current constraints. Stepping into the actual power and possibilities that each individual has in a life sciences company can foster innovation. Optimizing a single piece of technology or process step of the clinical trial value chain does not provide the benefits often promised. And you cannot solve people problems with technology or process solutions.We speak about how remote work in life sciences worked really well during the pandemic. But that it somehow stopped working. This is in fact a well understood phenomenon, where we initially could ride on the connections created pre-pandemic: Now as teams have experienced churn, people can no longer rely on that personal connection. .And remote connection does not substitute the connections forged in person. Clinical trials often consist of people working for different organizations - like sponsors and CROs - who still need to gel together to do good work. To make this work, you need to be intentional to make this work. A lack of teamwork is often the root cause for poor performance in a clinical trial. We speak about the key challenges in pharma right now, and how companies are shifting towards rare dieseases. And how the current toolkit we have does not suit the problem. Guest:Tirrell Paytonhttps://www.linkedin.com/in/tirrellpayton/ Nooma Grouphttps://www.noomagroup.com/  ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Philip Russmeyer, Founder & CEO of Fitfile, about the promises that true data anonymization holds for transforming clinical trials. We dive into the differences between tokenization, anonymization and pseudonymisation of data. And how the difference is whether individuals can ever be identified or if the data is masked with a token that can potentially be removed. The risk of secondary use of data that has been tokenized has held back research and data sharing between healthcare and life sciences. One of the reasons is that collecting consent from individuals costs about 400 USD per consent.One of the downsides of anonymization is that data cannot be unified across sources for an individual to get a full picture of health data. We speak about the differences between US and EU attitudes and legislation about personal data protection and how these are converging towards stronger privacy protection. For good reason, since personal health data is worth 10x more on the dark web compared to financial data. Collection of consent also matters in the sense that 80-90% of a trial is still delayed due to longer recruitment timelines than anticipated. That can be reduced if the trial protocol rests on a larger volume of anonymized relevant data.Anonymized data can also serve as a larger and more ethical control arm for clinical trials. Same goes for long-term follow up of clinical trials and the potential to re-use data collected once in additional trials.   We speak about the siloed nature of health data between healthcare and life sciences and how Fitfile attempts to work end-to-end between the entire data creation lifecycle. Which is not always simple, but optimises the use of health data.  Guest:https://www.linkedin.com/in/philiprussmeyer/ Fitfilehttps://www.linkedin.com/company/fitfile/ Notes: GPDPR Program of the NHS: https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/general-practice-data-for-planning-and-research European Journal of Human Genetics: https://www.nature.com/ejhg/ ADPPA:https://www.congress.gov/bill/117th-congress/house-bill/8152/text ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we host Sam Ewing, who is the Global Head of Pharma Partnerships at Doccla. We speak about endpoint development in general - and digital endpoint development in particular. We define digital endpoints as something that happens in a patient's home, and is mediated by a smartphone with some technology associated with it. The benefits of digital endpoints for patients are tangible. They would not need to visit sites as often. That would make it easier to be a trial participant, and increase the diversity of clinical trial participants. That in turn would lead to better ecological validity of the data.We also speak about how a virtual ward is analogous to decentralised trials and how some of the data collected in a virtual ward setting could be used for clinical trials - potentially reducing the scale and complexity of clinical trials in the future.  Connecting the healthcare system and the clinical research setting could mean that we can re-use the data collected in one or the other setting.Guest:Samuel Ewinghttps://www.linkedin.com/in/samuelewing/Docclahttps://www.linkedin.com/company/doccla/ Notes:Digital endpoint approvalhttps://www.clinicalresearchnewsonline.com/news/2023/02/16/a-long-time-coming-on-digital-endpoints Digital Medicine Initiativehttps://dimesociety.org/________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we host Christian Born Djurhuus, who is a physician by training, a self-proclaimed geek and has had an impressive career in life sciences in the intersections between drug development, leadership and technology. We speak about how the waterfall mentality is prevalent in life sciences, where specifications are developed by one group and tossed over the fence to the next group. This creates friction and elongates development timelines. But there is also a challenge with developing drugs without the necessary feedback from the market - or that the market moves on from the initial dream of how a drug would perform in the market. We speak about how no matter how well we plan out drug development, risks will materialize. Planning may give an illusion of control, but the mentality of understanding that a plan is a nice baseline to navigate according to, but not actual reality, is crucial for navigating. Christian predicts that our industry will pivot towards developing patient solutions to a higher degree rather than drugs alone. These need to be tailored to the diseases they are targeting - but also patient profiles. We dive into how speaking to each other across professional domains is key to creating most possible value. But also that domain knowledge is essential for digitization. The life cycles of technology and health are very different. We speak about the example of Chat GPT and drug development lifecycles - but also those of organizations. And that life sciences needs to catch up to the speed of technology. Guest:Christian Born Djurhuushttps://www.linkedin.com/in/christian-born-djurhuus-58a4395/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Simon Taylor, Head of European Solutions Consulting at Florence Healthcare. We focus on site oriented technology transformation. We speak about the current challenges that clinical sites face, such as the high degree of churn within the healthcare industry, the increasing complexity of protocols and the prevalence of paper as the primary recording mechanism. We speak about how to help sites quit their paper dependencies, and how the regulatory landscape stands in the way of adapting more digital ways of working.  Sites have been given technologies to use by the sponsors that have not worked for them in the past - and have created an expectation that technology will not help make the process easier. We speak about the discrepancies between CROs, sponsors and sites. And how there is room for improvement to ensure that everyone wins from collaboration. Decentralized clinical trials are not well equipped to adopt additional technologies unless they can successfully move all of their processes into a more digital operating model on a more fundamental level.  The regulatory agencies have been encouraging diversity in clinical trial recruitment. Representation in research is currently skewed, so additional focus is needed. But it translates into a new kind of work for clinical sites - of physically going to new areas to recruit patients. Guest:Simon Taylorhttps://www.linkedin.com/in/simon-taylor-56143638/Florence Healthcarehttps://www.florencehc.com/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we speak to Ole Henriksen, Associated Partner of Nordic Healthcare Group and pharmaceutical market access expert. We speak about how health technology assessments (HTA) has impacted how we conduct clinical trials. Health Technology Assessment (HTA) emerged first as a research area in decision aids. Later, during the 1990s, as a formal requirement for reimbursement.Due to it being a requirement in many markets, it is often called “the 4th hurdle”.  It should be understood in addition to regulatory requirements on efficacy, safety and quality, HTA poses a 4th requirement of therapeutic value or value for money.The main purpose of conducting an assessment in the first place is to inform decision making. The research question or decision problem is: Should we include the technology as part of standard of care (and reimburse it)?Historically clinical trials were used to gain market access by passing regulatory requirements – efficacy, safety and quality. The emergence of HTA meant that data and information on the technologies at time of marketing should also be used to assess the value of the technology vs. existing clinical practice and in clinical practice.This is perhaps one of the big dilemmas in medical development today that we have regulatory authorities who grant priority review/fast track and so on, but HTA authorities asking for more certain effects to be documented at reimbursement.Guest:Ole Henriksenhttps://www.linkedin.com/in/ole-henriksen-b911705/Nordic Healthcare Grouphttps://nordichealthcaregroup.com/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we are hosting Kimberly Tableman, Founder and CEO of ESPERO Health, and speak about how clinical trial protocols are being re-imagined in our industry. We dive into what a protocol actually is and what it describes. Protocols are currently being developed with a lot of manual research. WIth googling, phoning friends and re-using existing protocols in word documents. Trials today are being conducted in a more complex environment than before. This means that it is necessary to adapt the trial design as the trial is executed. Creating a trial and executing it unchanged is becoming more rare and requirements for additional digitization in this space are increasing. Trial design is also a very collaborative process involving 10-12 stakeholders. Using a system that supports collaborative creation is key to avoid the pitfalls of versioning and overwriting of comments. Writing the protocol with data collected from the current market can make the protocol more robust and accelerate timelines. That is what Espiro health aims to provide in their protocol platform. Making it easy is the trick to ensure adoption. We also speak about the dynamics that lead to rigidity in the pharmaceutical space and how having sufficient inflow of money in especially big pharma leads to containing the status quo. Speaking out of her experience as a founder, we dive into what it means to start a technology company in the life sciences space and how funding is key to getting off the ground. Guest:Kimberly Tablemanhttps://www.linkedin.com/in/kimberly-tableman/ESPERO Healthhttps://www.linkedin.com/company/espero-health/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

This week we have André Chagwedera in the studio, the Founder and CEO of Fleming Protocol. We focus on health data, and what it would mean for patients to own their data. One of the consequences of patients owning their data would be that patient communities would have a say in which areas to conduct clinical research in as well as the design of clinical protocols.Fleming Protocol is a patient peer-to-peer network built on the blockchain. Where Fleming Protocol focuses on providing the tooling to make this network work, they work closely with patient communities, researchers and industry to understand the currently unmet needs and funnel those into research.Having built the solution on the blockchain builds traceability into the process of what gets funded and researched and how these priorities happen. We dive into how this would happen with the mechanisms in the blockchain as well as the needed competencies from the industry.  Guest:André Chagwedera https://www.linkedin.com/in/andrechagwedera/ Fleming Protocolhttps://flemingprotocol.io/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

We speak to Raj Indupuri, the co-founder & CEO of eClinical Solutions, about why data plays such a key role in our industry. And dispute this being true for as long as we have had clinical trials, the recent technological advancements open up the possibilities for true data-driven decision making. Even though the clinical space has been digitising for many years, digitization is not necessarily transformative. Pockets of evolution have been attempted in a siloed way - not reaching all the way across the value chain. This creates a fragmented experience for the end users. We speak about platforms and ecosystems of platforms, and how to make the collaboration between stakeholders and technology seamless. And maintaining systems openness. This means that competing providers need to collaborate - as frenemies - for the betterment of research.We imagine what the current transformation in the digital space means for internal IT departments in life sciences, and what kinds of skills and competencies are needed - and which are no longer required. This episode is a little different. Sam works for the company that Raj is the CEO of. And this time around Ivanna gets questions and answers them too.  Guest:Raj Indupurihttps://www.linkedin.com/in/rajindupuri/ eClinical Solutionshttps://www.eclinicalsol.com/ ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

Today we speak with Lars Rosendal, the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an innovation game - and how both governments and patients are willing to pay for innovation.Patients in many major diseases are well served. That means we need to push the innovation to bring something to market that is either much safer, or has a higher degree of efficacy. When it comes to bringing a drug through the entire clinical value chain, there is a lot of uncertainty as it is. When you are trying to aim for innovation, the uncertainty increases. What this uncertainty does to a company depends on the company size. Being in a mid-sized pharmaceutical company means that there is some room for taking risks, but also a need to balance the uncertainty with the need to ensure continued operations. We dive into what this means for trial design in different stages of clinical trials - and how some of these stages can be outsourced, whereas others should be best kept in house to build relationships with HCPs pre-drug launch. We speak about leadership in the clinical area - and the benefits of understanding the entire clinical life cycle. Drug development is both an innovation game and a horse race. Leadership is what will allow your organization to run fast - but also dare to fail in pursuit of a deep purpose. Lars recently re-organized his leadership team to structurally ensure cross-functional collaboration and drive a competitive edge. We speak about the ideas behind this restructuring, and also how it has addressed some of the most stubborn challenges of our industry. Off-mic, Lars Rosendal and Ivanna Rosendal did try to figure out if there is a family relation - but there did not appear to be one.  Guest:Lars Rosendalhttps://www.linkedin.com/in/lars-rosendal-2520a16/ LRXDK@leo-pharma.com ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page

In this episode we speak to Rebecca Godfrey, the author of The Leadership Vaccine, about transforming specialists into leaders. In The Leadership Vaccine we follow a story of how a company transforms itself - and discovers the five pillars of leadership.We speak about how the state of leadership in life sciences is improving as the science of leadership is gaining a more prominent position. And how the regulatory requirements of our industry can bring forth creative potential in leadership.    We discuss how leadership may not require technical expertise, and the difference between leading people and leading delivery - and why separating line management from delivery management can be beneficial for specialists. Line management should not be the only way to progress in your career.   Another topic we discuss is how to foster cross-functional collaboration - and how creating a shared responsibility in the leadership team leads to high performance. Rebecca also takes us through the five pillars of leadership as she describes in the book and why they together make an organization click into place. Guest:Rebecca Godfreyhttps://www.linkedin.com/in/rebecca-godfrey/The Leadership Vaccine:https://www.amazon.com/Leadership-Vaccine-innovation-efficiency-resilience/dp/1781334536 ________Reach out to Sam Parnell and Ivanna RosendalJoin the conversation on our LinkedIn page